持久性低血压的风险因素与5-氨基氨酸相关:一个单一机构的回顾性研究
Naoto Okada1, Hikaru Kimura1, Masakazu Ozaki1
1Pharmacy Department, Yamaguchi University Hospital, Yamaguchi 755-8505, Japan.
Biological & pharmaceutical bulletin
|February 18, 2026
概括
膀癌的5-阿米诺列武林酸 (5-ALA) 光动力学诊断后持续的低血压与手术前血红蛋白水平的降低有关. 这一发现可能有助于识别患有长期低血压术后风险较高的患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医学诊断 医学诊断 医学诊断
背景情况:
- 5-阿米诺列武林酸 (5-ALA) 用于膀癌的光动力学诊断 (PDD),诱导光用于瘤可视化.
- 低血压是已知的5-ALA PDD的不良影响,之前的研究主要集中在给药后的事件.
- 持续性低血压,延长超过5-ALA的管理的一天,需要持续的患者管理,但其风险因素尚未明确定义.
研究的目的:
- 为了确定与持续性低血压相关的风险因素,在为膀癌PDD给予5-ALA后.
- 调查手术前临床特征与手术后持续低血压的发展之间的关系.
主要方法:
- 一项回顾性研究分析了263名接受膀癌5-ALA PDD治疗的患者.
- 根据给药后一天的血压,患者被分为持久性 (n=30) 和非持久性 (n=153) 低血压组.
- 使用多变量逻辑回归和接收器操作特征 (ROC) 曲线分析来识别风险因素和预测低血压.
主要成果:
- 在持久性低血压组中,手术前的血红蛋白水平与非持久性低血压组相比显著降低 (p < 0.05).
- 术前较低的血红蛋白被确定为持续低血压的独立风险因素 (OR,0.76;95% CI,0.60-0.97).
- 一个ROC曲线分析确定了手术前血红蛋白切割值12.9g/dL,用于预测持续的低血压.
结论:
- 在膀癌患者中,手术前的血红蛋白水平是5-ALA PDD后持续性低血压的重要独立风险因素.
- 手术前血红蛋白水平低于12.9g/dL可能表明患长期低血压的风险增加.
- 这些发现表明,手术前血红蛋白评估可能有助于分层患者,这些患者有持续的5-ALA诱导的低血压风险,指导术后护理.
相关概念视频
Alterations in Blood Pressure
2.3K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
2.3K
Drug Toxicity: Risk factors
27
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
27
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
282
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
282
Hypertension III: Clinical Manifestations and Diagnostic Studies
636
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
636
Factors Affecting Protein-Drug Binding: Patient-Related Factors
354
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
354
Factors Affecting Renal Clearance: Renal Impairment
509
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
509


